{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalEntity"
  ],
  "@id": "aku-020-anticoagulation",
  "metadata": {
    "version": "3.0.0",
    "created": "2025-12-30T04:37:00.000Z",
    "contributors": [
      "copilot-agent",
      "vascular-surgery-knowledge-base",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "last_updated": "2025-12-30T04:37:00.000Z",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/mesenteric-ischemia",
    "type": "treatment",
    "difficulty": "advanced",
    "importance": "high",
    "aku_id": "020",
    "keywords": [
      "anticoagulation",
      "heparin",
      "warfarin",
      "thrombosis prevention",
      "embolic protection"
    ],
    "medical_specialty": "vascular_surgery",
    "isNativeDomain": true
  },
  "content": {
    "statement": "aku-020-anticoagulation is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Mesenteric-Ischemia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding aku-020-anticoagulation helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of aku-020-anticoagulation include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of aku-020-anticoagulation."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "acute_anticoagulation": {
    "timing": "Immediately upon clinical suspicion",
    "agent_of_choice": "Unfractionated heparin (UFH)",
    "regimen": {
      "bolus": "80 U/kg IV bolus (typical ~5000 U)",
      "infusion": "18 U/kg/hr, titrate to aPTT 1.5-2.5x normal",
      "monitoring": "aPTT every 6 hours until stable"
    },
    "rationale": [
      "Prevents thrombus propagation",
      "Limits extension of ischemia",
      "Reversible for surgery",
      "Familiar to all providers"
    ],
    "why_UFH_preferred": [
      "Rapidly reversible with protamine",
      "Short half-life (1-2 hours)",
      "Can be held for surgery and restarted",
      "Dose adjustable based on response"
    ]
  },
  "by_etiology": {
    "embolic_AMI": {
      "acute": "UFH as above",
      "perioperative": "May hold for surgery, restart post-op",
      "long_term": "Warfarin or DOAC for underlying AF or cardiac source",
      "duration": "Often lifelong if AF present",
      "target_INR": "2.0-3.0 for AF"
    },
    "thrombotic_AMI": {
      "acute": "UFH as above",
      "perioperative": "Continue post-op to protect revascularization",
      "long_term": "Antiplatelet therapy (aspirin) for atherosclerosis",
      "statin": "High-intensity statin for secondary prevention"
    },
    "mesenteric_venous_thrombosis": {
      "acute": "UFH as above",
      "transition": "Transition to warfarin or DOAC",
      "duration": {
        "provoked": "3-6 months if reversible cause",
        "unprovoked": "Often indefinite",
        "thrombophilia": "Based on specific condition, often lifelong"
      },
      "special_note": "Anticoagulation is often the ONLY treatment needed for MVT"
    },
    "NOMI": {
      "anticoagulation_role": "Secondary, not primary treatment",
      "focus": "Hemodynamic optimization, vasodilator therapy",
      "consider": "Prophylactic heparin for VTE prevention"
    }
  },
  "perioperative_management": {
    "before_surgery": {
      "hold_time": "May continue until just before incision",
      "reversal": "Protamine if excessive bleeding"
    },
    "during_surgery": {
      "embolectomy": "Intraoperative heparin (5000 U) before clamp",
      "bypass": "Intraoperative heparin, may not reverse"
    },
    "after_surgery": {
      "restart": "Within 12-24 hours if hemostasis adequate",
      "bridging": "Continue UFH until therapeutic on warfarin if indicated"
    }
  },
  "long_term_options": {
    "warfarin": {
      "indication": "AF, mechanical valve, MVT",
      "target_INR": "2.0-3.0 (higher for mechanical valve)",
      "advantages": "Long experience, reversible",
      "disadvantages": "Monitoring required, drug/food interactions"
    },
    "DOACs": {
      "agents": [
        "Apixaban",
        "Rivaroxaban",
        "Dabigatran",
        "Edoxaban"
      ],
      "indication": "AF, VTE (MVT included)",
      "advantages": "No monitoring, fixed dosing",
      "disadvantages": "Renal adjustment, limited reversal agents",
      "evidence_in_MVT": "Limited but growing, generally accepted"
    },
    "antiplatelet": {
      "aspirin": {
        "indication": "Atherosclerotic disease without embolic source",
        "dose": "81-325 mg daily"
      },
      "clopidogrel": {
        "indication": "After stenting, aspirin allergy",
        "dose": "75 mg daily"
      },
      "dual_antiplatelet": {
        "indication": "After mesenteric stenting",
        "duration": "1-6 months, then aspirin alone"
      }
    }
  },
  "contraindications_and_cautions": {
    "relative_contraindications": [
      "Active bleeding",
      "Recent major surgery",
      "Severe thrombocytopenia",
      "History of HIT"
    ],
    "management": "In AMI, benefits almost always outweigh risks",
    "HIT_alternative": "Argatroban, bivalirudin"
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "urn:wskg:medicine:surgery:vascular:pathology:mesenteric-ischemia:019",
        "title": "Initial Resuscitation",
        "strength": 1.0
      }
    ],
    "enables": [
      {
        "id": "urn:wskg:medicine:surgery:vascular:pathology:mesenteric-ischemia:021",
        "title": "Open Surgical Revascularization",
        "strength": 0.9
      }
    ],
    "skos:broader": [
      "http://dbpedia.org/resource/Knowledge"
    ],
    "skos:related": [
      "http://dbpedia.org/resource/Concept"
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Concept"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). aku-020-anticoagulation. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "pedagogical": {
    "target_audience": [
      "vascular_surgery_residents",
      "emergency_physicians",
      "hospitalists"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "Understand the rationale for immediate anticoagulation in AMI",
      "Know dosing and monitoring for UFH",
      "Select appropriate long-term anticoagulation by etiology",
      "Manage anticoagulation perioperatively"
    ],
    "clinical_pearls": [
      "Start heparin on SUSPICION, not confirmation",
      "MVT may be treated with anticoagulation alone",
      "Protect your revascularization with post-op anticoagulation",
      "Long-term therapy depends on etiology (AF \u2192 anticoagulation, atherosclerosis \u2192 antiplatelet)"
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Concept",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}